Cancer - Sparx Biotech
Cancer
Status:
Active, open to accrualClinicalTrials.gov:
NCT06259552A Phase 1, Open-label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of an anti-LIBRB2 / PD-L1 bispecific antibody SPX- 303 in Patients with Solid Tumors